- Y Diweddaraf sydd Ar Gael (Diwygiedig)
- Gwreiddiol (a wnaed Fel)
The Human Medicines Regulations 2012, SCHEDULE 7A is up to date with all changes known to be in force on or before 19 August 2024. There are changes that may be brought into force at a future date. Changes that have been made appear in the content and are referenced with annotations.
Revised legislation carried on this site may not be fully up to date. Changes and effects are recorded by our editorial team in lists which can be found in the ‘Changes to Legislation’ area. Where those effects have yet to be applied to the text of the legislation by the editorial team they are also listed alongside the legislation in the affected provisions. Use the ‘more’ link to open the changes and effects relevant to the provision you are viewing.
Whole provisions yet to be inserted into this Instrument (including any effects on those provisions):
Regulation 45N(5)(b)
Textual Amendments
F1Sch. 7A inserted (20.8.2013) by The Human Medicines (Amendment) Regulations 2013 (S.I. 2013/1855), regs. 1(1), 33
1. The name and address of the applicant.U.K.
2. The name and address of the person (if any) making the application on the applicant’s behalf.U.K.
3. The address of each of the premises where any operations to which the registration relates are to be carried out.U.K.
4. The address of any premises not mentioned by virtue of the above requirement, where—U.K.
(a)the applicant proposes to keep any living animals, from which substance(s) used in the production of the active substance(s) to which the application relates are to be derived;
(b)materials of animal origin from which an active substance is to be derived, as mentioned in the above sub-paragraph, are to be kept.
5. The address of each of the premises where active substances are to be stored, or from which active substances are to be distributed.U.K.
6. The address of each of the premises where any testing associated with the manufacture or assembly of active substances to which the registration relates.U.K.
7. The name, address, qualifications and experience of the person whose duty it will be to supervise any manufacturing operations, and the name and job title of the person to whom they report.U.K.
8. The name, address, qualifications and experience of the person who will have responsibility for the quality control of active substances, and the name and job title of the person to whom they report.U.K.
9. The name, address, qualifications and experience of the person whose duty it will be to supervise any importation, storage or distribution operations, and the name and job title of the person to whom they report.U.K.
10. The name, address and qualifications of the person to be responsible for any animals kept as mentioned in paragraph 4(a).U.K.
11. The name, address and qualifications of the person to be responsible for the culture of any living tissue for use in the manufacture of an active substance.U.K.
12. For each active substance to be manufactured, imported, or distributed—U.K.
(a)the CAS registration number assigned to that active substance by the Chemical Abstracts Service, a division of the American Chemical Society;
(b)where applicable, the Anatomical Therapeutic Category code assigned to that active substance under the Anatomical Therapeutic Chemical Classification System used for the classification of drugs by the World Health Organisation’s Collaborating Centre for Drug Statistics Methodology;
(c)either—
(i)the International Union of Pure and Applied Chemistry nomenclature, or
(ii)the common name; and
(d)the intended quantities of each active substance to be manufactured, imported or distributed.
13. Details of the operations to which the registration relates, including a statement of whether they include—U.K.
(a)the manufacture of active substances;
(b)the importation of active substances F2...;
(c)the storage of active substances; or
(d)the distribution of active substances.
Textual Amendments
F2Words in Sch. 7A para. 13(b) omitted (31.12.2020) by virtue of The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/775), regs. 1, 43(2); 2020 c. 1, Sch. 5 para. 1(1)
14. A statement of the facilities and equipment available at each of the premises where active substances are to be manufactured, stored or distributed.U.K.
15. A statement as to whether the particular active substances are intended for—U.K.
(a)use in a medicinal product with an EU marketing authorisation;
(b)use in a special medicinal product; or
(c)export F3....
Textual Amendments
F3Words in Sch. 7A para. 15(c) omitted (31.12.2020) by virtue of The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/775), regs. 1, 43(3); 2020 c. 1, Sch. 5 para. 1(1)
16. A separate statement in respect of each of the premises mentioned in the application of—U.K.
(a)the manufacturing, storage or distribution operations carried out at those sites, and the specific active substances to which those activities relate; and
(b)the equipment available at those premises for carrying out those activities.
17. A statement of the authority conferred on the person responsible for quality control to reject unsatisfactory active substances.U.K.
18. A description of the arrangements for the identification and storage of materials before and during the manufacture of active substances.U.K.
19. A description of the arrangements for the identification and storage of active substances.U.K.
20. A description of the arrangements at each of the premises where the applicant proposes to store active substances for ensuring, as far as practicable, the turn-over of stocks of active substances.U.K.
21. A description of the arrangements for maintaining—U.K.
(a)production records, including records of manufacture and assembly;
(b)records of analytical and other tests used in the course of manufacture or assembly for ensuring compliance of materials use in manufacture, or of active substances, with the specification for such materials or active substances;
(c)records of importation;
(d)records of storage and distribution.
22. A description of the arrangements for keeping reference samples of—U.K.
(a)materials used in the manufacture of active substances; and
(b)active substances.
23. Where the application relates to active substances intended for use in an advanced therapy medicinal product, an outline of the arrangements for maintaining records to allow traceability containing sufficient detail to enable the linking of an active substance to the advanced therapy medicinal product it was used in the manufacture of and vice versa.U.K.
24. Details of—U.K.
(a)any manufacturing, importation, storage or distribution operations, other than those to which the application for registration relates, carried on by the applicant on or near each of the premises, and
(b)the substances or articles to which those operations relate.]
The Whole Instrument you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
The Whole Instrument you have selected contains over 200 provisions and might take some time to download.
Would you like to continue?
Yr Offeryn Cyfan you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
Yr Offeryn Cyfan heb Atodlenni you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
Y Rhestrau you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
Y Diweddaraf sydd Ar Gael (diwygiedig):Y fersiwn ddiweddaraf sydd ar gael o’r ddeddfwriaeth yn cynnwys newidiadau a wnaed gan ddeddfwriaeth ddilynol ac wedi eu gweithredu gan ein tîm golygyddol. Gellir gweld y newidiadau nad ydym wedi eu gweithredu i’r testun eto yn yr ardal ‘Newidiadau i Ddeddfwriaeth’.
Gwreiddiol (Fel y’i Deddfwyd neu y’i Gwnaed): Mae'r wreiddiol fersiwn y ddeddfwriaeth fel ag yr oedd pan gafodd ei deddfu neu eu gwneud. Ni wnaed unrhyw newidiadau i’r testun.
Rhychwant ddaearyddol: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.
Dangos Llinell Amser Newidiadau: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.
Mae Memoranda Esboniadol yn nodi datganiad byr o ddiben Offeryn Statudol ac yn rhoi gwybodaeth am ei amcan polisi a goblygiadau polisi. Maent yn ceisio gwneud yr Offeryn Statudol yn hygyrch i ddarllenwyr nad oes ganddynt gymhwyster cyfreithiol, ac maent yn cyd-fynd ag unrhyw Offeryn Statudol neu Offeryn Statudol Drafft a gyflwynwyd ger bron y Senedd o Fehefin 2004 ymlaen.
Gallwch wneud defnydd o ddogfennau atodol hanfodol a gwybodaeth ar gyfer yr eitem ddeddfwriaeth o’r tab hwn. Yn ddibynnol ar yr eitem ddeddfwriaeth sydd i’w gweld, gallai hyn gynnwys:
Impact Assessments generally accompany all UK Government interventions of a regulatory nature that affect the private sector, civil society organisations and public services. They apply regardless of whether the regulation originates from a domestic or international source and can accompany primary (Acts etc) and secondary legislation (SIs). An Impact Assessment allows those with an interest in the policy area to understand:
This timeline shows the different points in time where a change occurred. The dates will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. The first date in the timeline will usually be the earliest date when the provision came into force. In some cases the first date is 01/02/1991 (or for Northern Ireland legislation 01/01/2006). This date is our basedate. No versions before this date are available. For further information see the Editorial Practice Guide and Glossary under Help.
Defnyddiwch y ddewislen hon i agor dogfennau hanfodol sy’n cyd-fynd â’r ddeddfwriaeth a gwybodaeth am yr eitem hon o ddeddfwriaeth. Gan ddibynnu ar yr eitem o ddeddfwriaeth sy’n cael ei gweld gall hyn gynnwys:
liciwch ‘Gweld Mwy’ neu ddewis ‘Rhagor o Adnoddau’ am wybodaeth ychwanegol gan gynnwys